文献速递抗栓抗凝管理药物不良反应与药物警戒

直接口服抗凝药治疗肝素诱导血小板减少症急性期的疗效与安全性:系统综述

The efficacy and safety of direct oral anticoagulants in the treatment of the acute phase of heparin-induced thrombocytopenia: A systematic review.
PubMed 文献 · Am J Health Syst Pharm · 2024-01-01

该系统综述检索至2023年7月的文献,纳入12篇报告36例成人患者以DOAC作为HIT急性期初始治疗的研究。利伐沙班使用最多(28例),其次阿哌沙班(7例)和达比加群(1例);所有血小板减少患者均实现血小板恢复,1例发生深静脉血栓,无临床显著不良事件。作者认为DOAC用于HIT急性期可能是安全有效的治疗选择。

要点

  • 12篇文献共36例成人患者以DOAC作为HIT急性期初始治疗。
  • 利伐沙班使用28例,阿哌沙班7例,达比加群1例。
  • 所有血小板减少患者均实现血小板恢复,1例发生深静脉血栓。

核心结论

  • 来自12篇文献共36例患者的数据提示,DOAC用于HIT急性期可能是安全有效的治疗选择,且监测与管理便利。

研究设计与样本

  • 系统综述检索PubMed、MEDLINE、Embase和Web of Science Core Collection至2023年7月。
  • 初检1188篇,去重后审阅770篇,最终纳入12篇。
  • 纳入对象为以DOAC作为HIT急性期初始治疗的成人患者。

主要发现

  • 利伐沙班为最常用DOAC(28例),其次阿哌沙班(7例)和达比加群(1例)。
  • 所有血小板减少患者均实现血小板恢复,其中2例血小板计数正常。
  • 1例发生深静脉血栓,无其他新发或复发性血栓。
  • 未报告任何临床显著不良事件。

关键数值与推荐

  • 阿加曲班和比伐卢定需静脉输注并密切监测aPTT和调整剂量。
  • 磺达肝癸钠需注射,且体重<50kg者禁用。
  • DOAC可提供口服治疗HIT急性期的能力,监测需求少且给药方案一致。

临床怎么用

  • DOAC可作为HIT急性期初始治疗的口服选择,尤其当静脉抗凝监测不便时。
  • 使用DOAC期间仍需关注血栓复发和出血风险,尽管本综述未报告临床显著不良事件。
  • 选择DOAC时需考虑患者体重等因素,如磺达肝癸钠在体重<50kg者禁用。

局限性

  • 仅纳入12篇文献共36例患者,样本量小。
  • 利伐沙班使用最多(28例),其他DOAC证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the safety and efficacy of direct oral anticoagulants (DOACs) in the treatment of the acute phase of heparin-induced thrombocytopenia (HIT). SUMMARY: A systematic review of the literature was conducted on PubMed, MEDLINE, Embase, and Web of Science Core Collection through July 2023. Search terms included "heparin-induced thrombocytopenia AND direct-oral-anticoagulants" in addition to a list of oral anticoagulants. Adult patients who used direct oral anticoagulants as the initial treatment for the acute phase of HIT were included. A total of 1,188 articles were initially identified, with 770 articles reviewed following removal of duplicates. Following the application of inclusion and exclusion criteria, 12 articles were ultimately included. Rivaroxaban was the most-utilized DOAC (28 patients), followed by apixaban (7 patients) and dabigatran (1 patient). All patients with thrombocytopenia demonstrated successful platelet recovery, with two patients presenting with normal platelet counts. One patient developed a deep venous thrombosis with no other new or recurrent thromboses. There were no reported clinically significant adverse events in any patient. Obstacles and deterrents to the use of the standards of care in the acute phase of HIT exist. Argatroban and bivalirudin require intravenous infusion and require close aPTT monitoring and dose adjustment. Fondaparinux requires injection and is contraindicated with body weight <50kg. DOACs would offer the novel ability for an oral treatment in the treatment of the acute phase HIT and allow for minimal monitoring and consistent dosing strategies. Therefore, DOACs are an intriguing choice for the treatment of the acute phase of HIT. CONCLUSION: Data from 12 publications and across 36 patients suggests that the use of DOACs in the acute phase of HIT may be a safe and efficacious treatment option with favorable ease of monitoring and management.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Sadowski C, Reinert JP. The efficacy and safety of direct oral anticoagulants in the treatment of the acute phase of heparin-induced thrombocytopenia: A systematic review. Am J Health Syst Pharm. 2024. PMID: 38651828. doi:10.1093/ajhp/zxae109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。